1 SCREENING. 2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?

Slides:



Advertisements
Similar presentations
Screening and Prevention
Advertisements

Lecture 3 Validity of screening and diagnostic tests
Critically Evaluating the Evidence: diagnosis, prognosis, and screening Elizabeth Crabtree, MPH, PhD (c) Director of Evidence-Based Practice, Quality Management.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
Melissa Ewerth Graduate Adapted Physical Education, WCU.
Azita Kheiltash Social Medicine Specialist Tehran University of Medical Sciences Diagnostic Tests Evaluation.
MEASURES OF DISEASE ASSOCIATION Nigel Paneth. MEASURES OF DISEASE ASSOCIATION The chances of something happening can be expressed as a risk or as an odds:
Diagnosing – Critical Activity HINF Medical Methodologies Session 7.
Monitoring and Screening HINF Medical Methodologies Session 10.
Screening. Screening refers to the application of a test to people who are as yet asymptomatic for the purpose of classifying them with respect to their.
Overdiagnosis as an extreme form of length-time bias Breast cancer screening as example Juan Gérvas, MD, PhD, Equipo CESCA, Madrid, Spain
How do we know whether a marker or model is any good? A discussion of some simple decision analytic methods Carrie Bennette on behalf of Andrew Vickers.
Statistics for Health Care
Screening revision! By Ilona Blee. What are some UK Screening programmes?  Antenatal & newborn screening  Newborn Blood Spot  Newborn Hearing Screening.
Prof. Wasantha Gunathunga.  Primary  Secondary  Tertiary.
Screening and Early Detection Epidemiological Basis for Disease Control – Fall 2001 Joel L. Weissfeld, M.D. M.P.H.
The Nature of Disease.
Multiple Choice Questions for discussion
Inference in practice BPS chapter 16 © 2006 W.H. Freeman and Company.
Screening.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Thomas B. Newman, MD, MPH Andi Marmor, MD, MSEd October 21, 2010.
Lecture 4: Assessing Diagnostic and Screening Tests
Statistics for Health Care Biostatistics. Phases of a Full Clinical Trial Phase I – the trial takes place after the development of a therapy and is designed.
Principles and Predictive Value of Screening. Objectives Discuss principles of screening Describe elements of screening tests Calculate sensitivity, specificity.
SCREENING Asst. Prof. Sumattna Glangkarn RN, MSc. (Epidemiology), PhD (Nursing studies)
Reliability of Screening Tests RELIABILITY: The extent to which the screening test will produce the same or very similar results each time it is administered.
Vanderbilt Sports Medicine How to practice and teach EBM Chapter 3 May 3, 2006.
Saudi Diploma in Family Medicine / 24 1 Dr. Zekeriya Aktürk Preventive Medicine and Periodic Health Examinations in Primary Care.
AUA VUR guidelines 2010 Methodology Twenty-one studies met the inclusion criteria (six were prospective), data were extracted and a meta-analysis was.
Dr K N Prasad Community Medicine
Screening and Diagnostic Testing Sue Lindsay, Ph.D., MSW, MPH Division of Epidemiology and Biostatistics Institute for Public Health San Diego State University.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Evaluation of Diagnostic Tests
“ Deal or no deal ” … Uncertainty Hannah, Daniela, Gill.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
 Volunteer bias  Lead time bias  Length bias  Stage migration bias  Pseudodisease.
Screening Puja Myles
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Prediction statistics Prediction generally True and false, positives and negatives Quality of a prediction Usefulness of a prediction Prediction goes Bayesian.
Screening of diseases Dr Zhian S Ramzi Screening 1 Dr. Zhian S Ramzi.
SCREENING TTTThe search for unrecognized disease or defect by means of rapidly applied tests, examinations or other procedures in apparently healthy.
Principles of Screening
Screening and its Useful Tools Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Health and Disease in Populations 2002 Sources of variation (1) Paul Burton! Jane Hutton.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Screening.  “...the identification of unrecognized disease or defect by the application of tests, examinations or other procedures...”  “...sort out.
12/12/2009Dr. Salwa Tayel1 Comunicación y Gerencia.
The Practice of Statistics Third Edition Chapter 11: Testing a Claim Copyright © 2008 by W. H. Freeman & Company Daniel S. Yates.
SCREENING FOR DISEASE. Learning Objectives Definition of screening; Principles of Screening.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
Diagnosis:Testing the Test Verma Walker Kathy Davies.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Medical Necessity Criteria An Overview of Key Components Presented by BHM Healthcare Solutions.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M
Cancer prevention and early detection
What is Screening? Basic Public Health Concepts Sheila West, Ph.D.
How do we delay disease progress once it has started?
What is Screening? Basic Public Health Concepts Sheila West, Ph.D.
Screening, Sensitivity, Specificity, and ROC curves
Dr. Hannah Jordan Lecturer in Public Health ScHARR
Introduction to public health surveillance
Breast Cancer.
No matter what the type of genetic screening, certain core principles should be followed before a program is introduced. Principles of Screening • The.
Screening and Prevention
Evidence Based Diagnosis
Presentation transcript:

1 SCREENING

2 Why screen? Who wants to screen? n Doctors n Labs n Hospitals n Drug companies n Public n Who doesn’t ?

3

4 Screening for Obesity n Do you feel obese? n Have you ever felt obese? n In the last month how often have you felt obese? 1-3 times, 4-10 times, more than 10 times n How long does each episode of obesity last? Less than 1 hour, 1-2 hours, more than 2 hours n Have you discussed your obesity with someone? n Who? Spouse, friend, doctor, pastor (religious figure) n Have you ever shopped at oversize or “big and tall” clothing stores? Once, two to 5 times, more than 5 times

5 Disease Screening Criteria for useful screening Disease should be: Common Serious Treatable Slow to become symptomatic Treatment in asymptomatic phase has to be superior to treatment after symptoms develop Test should be: Inexpensive Acceptable t patients and physicians Have high predictive values in the population to be screened

6 Disease Screening How to screen: which tests? n The effectiveness of a screening test depends on its predictive values. These are determined by sensitivity, specificity, and prevalence in the screened population. n The lower the prevalence, the higher the sensitivity and specificity have to be to justify use of the test. n If prevalence is too low, even with high sensitivity and specificity, the great majority of positives will not have the disease, and screening may be indefensible due to the high cost of following up all the healthy positives.

7 Disease Screening n Simplicity, cost, and safety: –The dictum "do no harm" is primary with screening, since it will be applied to many people for whom there is no evidence for the disease. n Thus, the screening test must be simple, cheap and safe. n Acceptability to patients and physicians: –If patients won't submit to it, or physicians won't recommend it or accept its results, forget it.

8 Disease Screening Risks of screening n Cost/risk of test. n False positives –psychological damage –risk of further testing –cost of further testing n False negatives – may delay diagnosis n Labeling –psychological –medical

9 Disease Screening n Labeling effects: –Statement of a diagnosis has an effect on the patient, distinct from any effects of the disease or its treatment. "Sick" vs. "Healthy" self-images and roles. n False positives, particularly due to multiple testing: –Beware screening by purely statistical criteria of "abnormality."

10

11 Disease Screening: Biases in evaluating screening programs Lead-time bias n If time to outcome (e.g., death) is measured from point of diagnosis, early diagnosis will increase the time to outcome (e.g., the length of survival) by the interval between diagnosis by screening, and when diagnosis would have occurred by ordinary means. n This can make early diagnosis appear to increase survival time, even when it has had no effect, or even a damaging effect.

12 Disease Screening: Biases in evaluating screening programs

13

14 Disease Screening: Biases in evaluating screening programs Length-time bias n The proportion of slowly progressing disease picked up by screening will be greater than the proportion picked up by standard clinical practice, since rapidly progressing disease will tend to become symptomatic more quickly. n Therefore, patients diagnosed by screening will, as a group, progress more slowly than those diagnosed by conventional means, even if early treatment has no impact.

15 Disease Screening: Biases in evaluating screening programs

16 Disease Screening: Biases in evaluating screening programs Compliance bias n Volunteers for screening are generally more health conscious/concerned than the general population, apt to assume greater responsibility for their own care, hence, more likely to comply with therapy. n So groups detected by screening may do better than others, not because early treatment matters, but because they comply with treatment more than others. This is not due to early detection by screening, but to the same reason that made them volunteer for screening in the first place. It is a "volunteer" bias.

17 Interpreting Medical Tests and Other Evidence Some take-home points n Single and combination diagnostic tests can be wrong. n Even correct tests just add information to what you already have, modifying the probabilities that a disease is present or absent. They don’t replace other clinical information from an hx and px. n The degree to which a test result warrants clinical action depends, strongly, on the circumstances of the test -- in particular, on the best assessment from all your contextual and clinical knowledge, of the chance of disease before the test is made. Identical test results may have entirely different implications for different patients, or in different environments.

18 Interpreting Medical Tests and Other Evidence Some take-home points n Highly accurate tests or test sequences (Se and Sp both high) can be clinically useless for some patients. n In particular: –when disease is unlikely to be present before the test, only a test with very high specificity can establish its presence (rule it in). Otherwise, most positive results will be errors. Such results can harm patients. –When disease is fairly likely to be present before a test, only a test with very high sensitivity can establish its absence (rule it out). Otherwise, most negative results will be errors. Such results can harm patients. n When a test can’t serve the desired purpose, it should not be ordered.